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Abstract
Analysis of th e  brain specific biomarkers amyloid ß42 (Aß42) and to ta l tau (t-tau) protein in 
cerebrospinal fluid (CSF) has a sensitivity and specificity o fm ore than 85%  for d ifferentiating  
Alzheim er's Disease (AD) from  non-dem ented controls. The com bination of Aß42 and phosphorylated  
tau (p-tau) proteins in CSF allows a differentiation betw een AD and VaD w ith  both a sensitivity and a 
specificity of around 85%. However, when CSF biomarkers are used to  d ifferen tia te  AD from  other 
dem entia syndromes, the  sensitivity and specificity are modest. International guidelines are 
contradictoryin th e ir advice on the  use of CSF biomarkers in AD diagnostics, resulting in a lack of 
consistency in clinical practice. W e present th ree  case-reports th a t illustrate clinical practice 
according to  the Dutch and European guidelines and portray th e  value o f CSF biom arker analysis as 
an add-on diagnostic to  th e  standard diagnostic workup fo r AD.
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INTRODUCTION
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the  
accumulation of extracellular senile plaques and intracellular neurofibrillary tangles. It is becoming 
increasingly im portant to  accurately diagnose AD at an early stage. An adequate diagnosis allows 
appropriate education, guidance, care and trea tm en t fo r patients and the ir inform al caregivers. 
Occupational therapy and caregiver support im prove quality of life fo r AD patients, while trea tm en t  
w ith acetylcholinesterase inhibitors can im prove cognitive function [1]. M oreover, potentially  
neuroprotective therapies fo r AD, which are currently under developm ent, are probably most 
beneficial w hen initiated at an early stage of the  disease [2].
According to  th e  current NINCDS-ADRDA diagnostic guidelines [3], defin ite  diagnosis of AD 
can only be m ade post-m ortem  by histopathological exam ination of the  brain. However, by using 
different diagnostic tools, such as neuropsychological tests and imaging techniques, a probable  
diagnosis can be achieved w ith reasonable sensitivity and specificity. Nowadays analysis of 
cerebrospinal fluid (CSF) biomarkers amyloid ß42 (Aß42), total tau (t-tau) and phosphorylated tau (p- 
tau ) is increasingly used to  d ifferen tia te  AD from  other dem entia disorders and non-dem ented  
patients. AD patients show a typical pattern  of decreased Aß42 and increased p-tau and t-tau . The 
com bination of decreased Aß42 and increased t-tau  has a sensitivity and specificity of m ore than 85%  
in d ifferentiating AD from  healthy controls [4, 5]. The addition of p-tau to  Aß42 and t-tau  fu rther 
increases specificity fo r AD [4]. M oreover, analysis of CSF biomarkers resulted in a correct diagnosis 
in 82%  of neuropathologically confirm ed AD and non AD cases [6]. A high NPV of 96% shows that 
normal CSF results m ake AD pathology very unlikely [7 ]. For d ifferentiating AD from  VaD, both the  
ratio of Aß42/p -ta u , and t-tau  x p -ta u / Aß42 yield sensitivities and specificities o f m ore than 85%  [8­
10]. W hen CSF biomarkers are used to  d ifferen tia te  AD from  dem entia syndromes such as 
fronto tem poral dem entia (FTD) and dem entia w ith  Lewy bodies (DLB), discrimination is more  
difficult. FTD can be discrim inated from  AD w ith  reasonable sensitivity and specificity, using the  t-
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ta u /A ß 42 ratio, and especially using p-tau, which is not elevated in FTD [11-14]. DLB patients show  
normal p-tau levels and low er tau levels com pared to  AD patients but overlap of values is still high, 
probably due to  mixed pathology in the  DLB group [15, 16].
The prevailing guidelines, NINCDS-ADRDA and the  DSM-IV-TR, do not include CSF biomarkers 
in AD diagnostics, since the  criteria w ere  developed before these biomarkers w ere  described [3]. The 
dem entia guidelines from  the  American Academ y of Neurology, which w ere  last revised in 2001, 
m ention CSF biomarkers but state th a t they are not appropriate fo r routine use in clinical practice
[17]. The m ore recent European Federation of Neurological Societies (EFNS) dem entia guidelines 
(2006) state th a t 'CSF Aß42, t-tau , and p-tau can be used as an adjunct in cases of diagnostic doubt'
[18]. Dutch guidelines state th a t CSF analysis o f these biomarkers are not part of the  standard  
diagnostic w ork up but can be taken into consideration when a higher diagnostic certainty is desired 
[19, 20]. M ore  specifically, they state th a t CSF analysis can be of additional value in patients under 65 
years of age whose differential diagnosis is broad, or in patients in w hom  imaging techniques and 
neuropsychological tests do not lead to  a clear-cut diagnosis. In 2007 a proposition was m ade for 
revising the  research criteria fo r the  diagnosis of AD [21]. This proposition states th a t a probable  
diagnosis of AD should be m ade using the  core diagnostic criteria of early subjective m em ory  
im pairm ents which gradually progress over m ore than 6 months, w ith  objective evidence of 
significant m em ory im pairm ent deficits supported by at least one of th ree  abnorm al biom arker 
values; i.e. abnorm al CSF biomarkers, abnorm al PET/SPECT scanning, or abnorm al MRI, th e  la tter tw o  
w ith the  hallmarks of m ediotem poral lobe hypoperfusion or atrophy. The som ew hat contradictory  
suggestions in the  guidelines result in inconsistency of routine diagnostics in clinical practice. W e  aim 
to  clarify th e  contribution of CSF biomarkers in clinical practice w ith th ree  typical case reports, and 
illustrate the need fo r an unambiguous guideline.
At the  Radboud University Nijmegen Medical Centre (RUNMC) m em ory clinic w e currently  
use CSF analysis according to  the  latest Dutch and European guidelines. The reference values fo r the
4
age group over 50 years th a t w e established in our own laboratory using the  sandwich ELISAs by 
Innogenetics are: Aß42 >500 ng/L, t-tau  <350 ng/L, p-tau <85 ng/L [8, 22]. These values are largely in 
line w ith  the reference values proposed in previous publications [5, 7]. In th e  last 1.5 years CSF 
analysis was perform ed in approxim ately 30 patients of the 200 patients th a t w e saw at our m em ory  
clinic. The following case reports w ere  selected from  this patient group to  exem plify th e  value of 
biom arker analysis in the  standard diagnostic workup fo r AD.
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Patient A is a 67 year old w om an, w ho had complaints about short term  m em ory loss. Her relatives 
noticed her repeatedly asking the  same questions. She had becom e insecure and started to  double  
check her own actions. A friend had to  help her w ith adm inistrative duties. Her complaints developed  
gradually over the  last one and a half year. She had a history o f hypertension and osteoporosis. She 
smoked 20 cigarettes a day from  th e  age of 15.
Neuropsychological tests indicated significant cognitive decline, w ith  a M ini M ental State 
Examination (M M SE) [23] score of 22 out of 30, and a Cambridge Cognitive Examination (CAMCOG, a 
section of th e  CAMDEX) [24] score of 81 out o f 104 (a higher score indicates a b e tte r perform ance; 
cut-off adjusted fo r age and education is 83). M ainly semantic m em ory function, both verbal and 
visually, recognition and orientation in tim e and place w ere  affected, w hile visuoconstruction, 
attention, executive functioning and cognitive speed w ere norm al. Therefore AD was suspected, 
m ore than VaD. The subsequent MRI showed extensive w h ite  m atter lesions (<25%  of w h ite  m atter), 
probably o f vascular-ischemic origin, next to  distinct atrophy w ith broadening of the  ventricles, and 
hippocampal atrophy grade 1 according to  Scheltens rating scale [25]. Because of these MRI results 
and th e  patient's vascular risk factors, a diagnosis of possible VaD was considered next to  AD. A 
lum bar puncture and fu rther neuropsychological testing was perform ed to  help clarify th e  diagnosis. 
The CSF biom arker levels w ere: Aß42 424  ng/L, t-tau  634  ng/L and p-tau 117 ng/L. The decreased level 
of Aß42 w ith  a significantly elevated t-tau  and p-tau and, consequently, an Aß42/p -ta u  ratio of 3.6, 
which is far below the cut-off ratio of 11.0 to  discrim inate VAD from  AD, supported the  diagnosis of 
AD over VaD, and therefore  w e diagnosed probable AD w ith cerebrovascular m orbidity [8]. 
Treatm ent w ith acetylcholinesterase inhibitors was initiated, which she to lerated  well. 17 months 
after diagnosis the  patient was stable w ithout fu rther deterioration in cognition, behavior or daily 
activities and no fu rther vascular disease hallmarks developed, supporting our initial diagnosis.
CASE REPORTS
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Patient B is a 63 year old w om an who was referred to  our clinic fo r a second opinion. The 
past tw o  years she had becom e increasingly anxious about new situations. She was having difficulty  
finding words and engaging in conversations. In 2007 a neurologist could not identify a cognitive 
disorder. At th a t tim e, she was diagnosed as having a dysthymic disorder and post-traum atic stress 
disorder by a psychiatrist and treated  w ith venlafaxine 75 mg, once daily. However, when she came 
to  our m em ory clinic 9 m onths later, her complaints had not disappeared. She still had difficulty 
engaging in conversations and could not finish her chores because she kept forgetting w hat she was 
doing. Due to  anxiety she stopped driving, in ternet banking and using th e  phone and video recorder, 
and there  was a severe loss of initiative. She had a MMSE score o f 21 out of 30, a CAMCOG score of 
68 out of 104 (cut-off adjusted fo r age and education is 83) and a geriatric depression scale (GDS) 
score of 2 out of 15 (a score above 7 indicates depression) [26]. These results suggested cognitive 
decline, possibly AD, since no other underlying disease was apparent, and history taking and GDS 
score showed th a t her depressive mood was in remission. The MRI, already m ade in 2007, was re­
evaluated and showed asymmetrical fron to tem poral atrophy w ithout medial tem poral lobe atrophy  
(figure I). A lum bar puncture was perform ed, because the  neuropsychological assessment and the  
MRI w ere not fully conclusive and still left the  possibility of AD diagnosis. CSF analysis showed normal 
levels o f all biomarkers (Aß42 560 ng/L, t-tau  335 ng/L and p-tau 77 ng/L). These results m ade an AD 
diagnosis less likely and could be com patible w ith  a diagnosis of FTD. Further specific 
neuropsychological testing was done, which showed below average learning curves w ith unimpaired  
delayed recall and recognition, decline in attention  and executive functions w ith  reduced inform ation  
processing speed and apathy. Apart from  a below average w ord fluency there  w ere  no language 
disorders. The com bination of MRI, CSF biom arker results and neuropsychological exam ination  
added to  the  likelihood of FTD. 15 months later the  patient had deteriorated mildly w ith  an MMSE  
now of 18 out of 30. No behavioral problems had occurred and her mood was stable. This clinical 
fo llow  up still leaves room fo r AD.
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Patient C is a 65 year old w om an w ho visited our m em ory clinic w ith  gradually increasing 
m em ory problems over the  past th ree  years. Her medical history revealed a subarachnoidal 
hem orrhage at th e  age of 33 due to  an aneurysm of the  anterior communicating artery, and excision 
of a frontal m eningeom a at the  age of 54. A fter exam ination w e objectified both verbal and visual 
m em ory dysfunctioning and disturbances in language, attention, visuoconstruction and executive  
functions ,which influenced her daily activities. Her MMSE score was 21 out of 30 w ith  a CAMCOG  
score of 80 out of 104 (cut-off adjusted fo r age and education is 83). W e  suspected a diagnosis of AD, 
but because of complicated history and young age, w e w anted  to  support this diagnosis w ith  
biom arker evidence. An MRI could not be perform ed because the  patient had a m etal clip on the  
cerebral aneurysm. A CT scan showed leftsided frontal atrophy and frontobasal atrophy of both 
hemispheres. CSF analysis was done, showing an Aß42 concentration of 431  ng/L,a t-tau  
concentration of 545 ng/L and a p-tau concentration of 118 ng/L. The decreased level of Aß42 and 
elevated t-tau  and p-tau confirm ed our notion of the  diagnosis possible AD. T reatm ent w ith  
cholinesterase inhibitors was initiated. A fter 16 months mild deterioration in m em ory function was 
seen, com patible w ith  the  diagnosis o f AD.
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DISCUSSION
These case reports illustrate th a t CSF analysis may be a valuable addition to  the  standard workup fo r 
AD, when used according to  th e  latest Dutch Diagnostic guidelines and th e  Dubois criteria for 
Alzheim er type pathology, although the la tter are proposed as research criteria and aw ait fu rther  
validation [19, 21]. These cases underline th a t in current clinical practice w e already frequently  refer 
to  these Alzheim er Disease research criteria, relying on positive AD-hallmarks, instead of the  classical 
NINCDS-ADRDA criteria th a t only w arran t AD diagnosis by exclusion of other systemic or brain 
diseases.
The first case shows the  affirm ative value of CSF biomarkers, w hen the  com bination of Aß42 
and p-tau indicates th a t a diagnosis of AD w ith vascular disease is m ore likely than VaD . The second 
case report displays the  use of CSF biomarkers when the  differential diagnosis is broader. In addition, 
m ore diagnostic certainty was desired because the patient came for re-evaluation, and MRI had not 
led to  a clear-cut diagnosis. The third case shows an exam ple o f a patient group in which MRI cannot 
be perform ed. O ther conditions th a t exclude MRI scanning include having a cardiac pacem aker or 
claustrophobia. As an alternative a CT-scan can be perform ed to  search fo r w h ite  m atter lesions and 
to  exclude a tum or, but th e  diagnostic value of CT images is lim ited by the  low er resolution and lower 
sensitivity fo r vascular lesions. M oreover, visualization of the  tem poral horn requires additional 
reconstruction and CT m ore often leads to  scatter artifacts. Therefore CSF analysis is regarded as a 
better alternative, w hen a lum bar puncture is not contra-indicated, e.g. in case of structural lesions.
The latest guidelines state th a t CSF analysis can be valuable in AD diagnostic work-up, only as 
an add-on diagnostic tool [21]. In certain cases the  CSF biomarkers can be of help in the differential 
diagnosis, both fo r confirming and excluding a diagnosis of AD. Due to  practical and occasionally 
medical circumstances, CSF analysis is not suitable to  be used as prim ary diagnostic tool fo r all 
patients investigated at a m em ory clinic. However, neither th e  invasiveness of lum bar puncture nor 
post-puncture complaints are, any longer a serious concern w ith m odern techniques, especially in
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older patients. In large series w ith  over 2000 patients zero complications have occurred, and the  
percentage o f older patients suffering from  post lum bar puncture pain is low, ranging from  0.9%  to  
4.1%  [27-29].
It m ight be argued th a t CSF analysis is lim ited by th e  high in ter-laboratory coefficient of 
variation [30, 31]. Even though processing and storage conditions have been standardized, in ter­
laboratory and intra-laboratory variation is still considerable [32]. However, once reference values 
have been established w ithin the  same laboratory, test results can be com pared and reproduced. In 
a previously perform ed retrospective diagnostic validation study of Aß42, t-tau  and p-tau in dem entia  
w e calculated optim al cut-offs fo r our population [33], because applying previously published criteria  
resulted in less optim al test results; e.g. fo r th e  Hansson criteria a sensitivity of 69% and specificity of 
61%  [7]. Using these reference values w e can reliably generate CSF biom arker values w ith a 
sensitivity of 96% and a specificity o f 97%, and draw  firm  conclusions from  them  [22].
So far, all CSF biomarkers studies have been carried out in selected patient cohorts as part of 
retrospective case control studies or in expert referral clinics, and predeterm ined cut-off values w ere  
usually not applied. Prospective studies should fu rther dem onstrate the  discrim inative value of CSF 
analysis in clinical practice. An exam ple is a recent study showing the  prognostic value of CSF 
biomarkers in patients w ith mild cognitive im pairm ent [34]. W e  feel that, in spite o f its limitations, 
CSF analysis already is a valuable add-on diagnostic measure, as illustrated by these case reports, in 
which predeterm ined cut-offs w ere  used. The prevailing guidelines, therefore , should be updated to  
ensure consensus on the  CSF application in clinical practice.
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Figure I. MRI of case 2. Transversal T2-FLAIR showing frontal cortical and asymmetrical left tem poral 
lobe atrophy.
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